MedTrace Logo

S100A8/A9 and Innate Immunity in Liver Disease

NCT05793983 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2023-03-31

No results posted yet for this study

Summary

This observational study evaluates the concentration of immune protein S100A8/A9 in different liver failure syndromes, its interaction with the immune system and validity as an immunotherapeutic target to improve survival in patients with advanced cirrhosis and/or acute on chronic liver failure.

Conditions

  • Cirrhosis, Liver
  • Immune Suppression
  • Liver Failure, Acute on Chronic
  • Ascites Hepatic
  • Infections

Sponsors & Collaborators

  • King's College Hospital NHS Trust

    collaborator OTHER

  • St George's, University of London

    lead OTHER

Principal Investigators

  • Arjuna Singanayagam, MBBS; PhD · St George's, University of London

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-09-28
Primary Completion
2023-09-01
Completion
2024-09-01

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05793983 on ClinicalTrials.gov